Global OEMs Will Launch First VA7000-Based Endoscopes, Signaling Strong Momentum for Valens Semiconductor's Medical Imaging Offering

Rhea-AI Summary

Valens Semiconductor (NYSE: VLN) said three OEMs will launch endoscopes powered by its VA7000 chipset, including an innovative laparoscope, a 3D robotic-surgery imaging solution, and the first single-use colonoscope with 4K video. The VA7000 includes built-in electrosurgical noise cancellation and supports multi-gig connectivity over ultra-thin coax and UTP cables. Valens says the VA7000 is the first chipset to comply with the MIPI A-PHY standard and will be shown at Medica, Nov 17–20, 2025 in Dusseldorf.

Positive

• Three VA7000-powered endoscopes to be launched by OEMs
• First single-use colonoscope with 4K video
• VA7000 includes electrosurgical noise cancellation
• VA7000 compliant with MIPI A-PHY standard

Negative

• No disclosed commercial terms or revenue timelines for launches
• Company depends on customer selection processes for product wins
• Forward-looking risks include supply chain and manufacturing delays

News Market Reaction

+1.27% 3.1x vol

12 alerts

+1.27% News Effect

+6.7% Peak in 6 min

+$2M Valuation Impact

$187M Market Cap

3.1x Rel. Volume

On the day this news was published, VLN gained 1.27%, reflecting a mild positive market reaction. Argus tracked a peak move of +6.7% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $187M at that time. Trading volume was very high at 3.1x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Three new endoscopes set to launch, including an innovative laparoscope, a 3D imaging solution for robotic surgeries, and the first single-use colonoscope with 4K video resolution

HOD HASHARON, Israel, Nov. 10, 2025 /PRNewswire/ -- Valens Semiconductor (NYSE: VLN) announced today that the first endoscopes powered by its VA7000 chipset will be launched by three OEMs, signaling strong momentum for Valens' entry into the medical imaging market. The products include an innovative laparoscope, a 3D imaging solution for robotic surgeries, and the first single-use colonoscope with 4K video resolution.

 

The Valens VA7000 chipset is the first on the market with built-in electrosurgical noise cancellation, providing reliable high-resolution video for endoscopic procedures. The chipset can also provide multi-gig connectivity over ultra-thin coax and UTP cables, allowing for unprecedented maneuverability of the endoscope.

"We're thrilled with how quickly the market is embracing our offering for medical imaging," said Gili Friedman, Head of the Cross-Industry Business at Valens Semiconductor. "We are encouraged to see leading companies proactively approaching us, recognizing our technology as a key enabler for the next generation of endoscopes. This demonstrates strong momentum in this important market for our company, and product-market fit that validates both our strategic direction and the unique advantages of our VA7000 chipset."

The VA7000 is the first chipset on the market to comply with the MIPI A-PHY standard. Having designed the chipset to operate flawlessly in the automotive industry's challenging electromagnetic environment, Valens is repurposing the VA7000 for other industries that share requirements for high performance connectivity, including medical, professional audio-video, and industrial machine vision.

Valens will display its endoscope offering next week at Hall 16/J23 of the Medica trade show taking place in Dusseldorf, Germany on November 17 to 20, 2025.

About Valens Semiconductor

Valens Semiconductor (NYSE: VLN) is a leader in high-performance connectivity, enabling customers to transform the digital experiences of people worldwide. Valens' chipsets are integrated into countless devices from leading customers, powering state-of-the-art audio-video installations, next-generation videoconferencing, and enabling the evolution of ADAS and autonomous driving. Pushing the boundaries of connectivity, Valens sets the standard everywhere it operates, and its technology forms the basis for the leading industry standards such as HDBaseT® and MIPI A-PHY. For more information, visit https://www.valens.com/.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding our anticipated future results, including financial results, our five-year plan, currency exchange rates, and contract wins, and future economic and market conditions. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Valens Semiconductor's ("Valens") management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Valens Semiconductor. These forward-looking statements are subject to a number of risks and uncertainties, including the cyclicality of the semiconductor industry; the effect of inflation and a rising interest rate environment on our customers and industry; the ability of our customers to absorb inventory; competition in the semiconductor industry, and the failure to introduce new technologies and products in a timely manner to compete successfully against competitors; if Valens fails to adjust its supply chain volume due to changing market conditions or fails to estimate its customers' demand; disruptions in relationships with any one of Valens' key customers; any difficulty selling Valens' products if customers do not design its products into their product offerings; Valens' dependence on winning selection processes; even if Valens succeeds in winning selection processes for its products, Valens may not generate timely or sufficient net sales or margins from those wins; sustained yield problems or other delays or quality events in the manufacturing process of products; our ability to effectively manage, invest in, grow, and retain our sales force, research and development capabilities, marketing team and other key personnel; our ability to timely adjust product prices to customers following price increase by the supply chain; our ability to adjust our inventory level due to reduction in demand due to inventory buffers accrued by customers; our expectations regarding the outcome of any future litigation in which we are named as a party; our ability to adequately protect and defend our intellectual property and other proprietary rights; our ability to successfully integrate or otherwise achieve anticipated benefits from acquired businesses; the market price and trading volume of the Valens ordinary shares may be volatile and could decline significantly; global political and economic uncertainty, including with respect to China-Taiwan relations; political, economic, governmental and tax consequences associated with our incorporation and location in Israel; and those factors discussed in Valens' Form 20-F filed with the SEC on February 26, 2025 under the heading "Risk Factors," and other documents of Valens filed, or to be filed, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Valens does not presently know or that Valens currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Valens' expectations, plans or forecasts of future events and views as of the date of this press release. Valens anticipates that subsequent events and developments may cause Valens' assessments to change. However, while Valens may elect to update these forward-looking statements at some point in the future, Valens specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Valens' assessment as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Logo - https://mma.prnewswire.com/media/2309625/4474760/Valens_Semiconductor_Logo.jpg

Press Contacts

Yoni Dayan
Head of Communications
Valens Semiconductor Ltd.
Yoni.dayan@valens.com

Hadley McKinnon
Senior Account Executive
Fusion PR
hadley.mckinnon@fusionpr.com

Investor Contacts

Michal Ben Ari
Investor Relations Manager
Valens Semiconductor Ltd.
michal.benari@valens.com

View original content:https://www.prnewswire.com/news-releases/global-oems-will-launch-first-va7000-based-endoscopes-signaling-strong-momentum-for-valens-semiconductors-medical-imaging-offering-302610078.html

SOURCE Valens Semiconductor

FAQ

What did Valens (VLN) announce on November 10, 2025 about medical imaging?

Valens announced three OEMs will launch endoscopes using its VA7000 chipset, including a 4K single-use colonoscope.

What are the technical advantages of the Valens VA7000 chipset for endoscopes?

The VA7000 offers electrosurgical noise cancellation and multi-gig connectivity over ultra-thin coax and UTP cables.

How is the VA7000 positioned relative to standards and markets for VLN?

Valens says the VA7000 is the first chipset to comply with the MIPI A-PHY standard and is repurposed from automotive to medical use.

When and where will Valens demonstrate its endoscope offering for VLN investors?

Valens will display the endoscope offering at Medica in Dusseldorf, Nov 17–20, 2025, Hall 16/J23.

Does the press release disclose revenue or contractual values from the OEM launches for VLN?

No; the release names product launches but does not disclose commercial terms, revenue, or contract values.